ProMIS expects to report six-month interim results from PRECISE-AD in the first half of 2026, with topline results ...

经过十余年迭代优化，科学家最终将靶点锁定在Aβ聚集级联反应中最具毒性的可溶性寡聚体阶段。新一代抗体药物终于突破瓶颈——2023年完全获批的仑卡奈单抗（Lecanemab）标志着精准医疗的重大突破。

Bristol-Myers Squibb (NYSE:BMY) recently announced positive topline results from its Phase 3 trials for Sotyktu, generating ...

CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate update.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...

TOKYO, Mar 25, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab) for the treatment of early ...

Eisai Inc. announced today that the company will present the latest findings from its robust neurology portfolio, including data on real-world experience and continued maintenance dosing with our dual ...

This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of ...

NEWTON, MA, USA I March 19, 2025 I Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that ...

This Perspective article examines the interplay between antibody diversification mechanisms and highlights the importance of constant regions in influencing the specificity and functionality of ...

Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to ...